サンプル依頼リスト カート
  • English
  • Korean
表紙：転移性乳がんの世界市場-2023年～2030年
市場調査レポート
商品コード
1374852

転移性乳がんの世界市場-2023年～2030年

Global Metastatic Breast Cancer Market - 2023-2030

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
転移性乳がんの世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

転移性乳がんはステージIVとも呼ばれ、乳がん細胞が骨、肺、脳、肝臓など体の他の部位に転移した場合に発生します。このがんが広がる過程は転移と呼ばれ、がん細胞が乳房の元の腫瘍から離れ、血流やリンパ系を通じて体の他の部位に移動することで起こります。

全身に転移した乳がんの治療には、通常、化学療法、ホルモン療法、標的療法、免疫療法などの全身療法が用いられます。場合によっては、手術や放射線療法などの局所療法が、身体の特定の部分を狙うために推奨されることもあります。

市場力学：市場促進要因と市場抑制要因

有病率の増加

転移性乳がんの有病率の増加は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、米国臨床腫瘍学会（ASCO）によると、米国では女性の約6％が初診時に転移性乳がんを患っています。

乳がんは、米国における女性のがんによる死亡の典型的な理由の第2位です。また、2023年には米国で約43,700人（女性43,170人、男性530人）の死傷者が出ると評価されています。さらに、米国医師会によると、早期乳がんの約20～30％が転移性乳がんやステージIVに移行します。このステージIVは、乳がんの中で最も激しく、壊滅的な状態であり、通常は対処しづらくなるまで無視されます。

さらに、他の要因の中でも、認知度の向上と研究活動は、予測期間中の世界市場の成長に貢献すると期待されています。

有効な治療法の不在

しかし、有効な治療法の不在や治療に関連した有害転帰は、予測期間中の転移性乳がん市場の成長を制限する可能性があります。さらに、認知度や専門家の不足も世界市場の成長を妨げる要因のひとつです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 有病率の上昇
    • 抑制要因
      • 有効な治療法の不在
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ分析
  • 特許分析
  • パイプライン分析
  • 疫学分析
  • SWOT分析
  • DMI見解

第6章 COVID-19分析

第7章 治療タイプ別

  • 化学療法
  • 免疫療法
  • ホルモン療法
  • 放射線療法

第8章 投与経路別

  • 経口
  • 非経口

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • がん研究センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Hoffmann-La Roche
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Pfizer Inc
  • Bristol-Myers Squibb, Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • AstraZeneca, Inc.
  • Amgen Inc.
  • Novartis AG
  • Merck and Co. Inc.

第13章 付録

目次
Product Code: PH7382

Overview

Metastatic breast cancer, also known as stage IV, occurs when breast cancer cells have spread to other parts of the body, such as the bones, lungs, brain, or liver. This process of cancer spreading is called metastasis, which happens when cancer cells break away from the original tumor in the breast and travel to other parts of the body through the bloodstream or the lymphatic system.

Systemic medications, such as chemotherapy, hormonal therapy, targeted therapies, and immunotherapy, are usually used to treat metastatic breast cancer throughout the entire body. In some cases, local treatments, such as surgery or radiation, may also be recommended to target a specific part of the body.

Market Dynamics: Drivers & Restraints

Growing Prevalence

The growing prevalence of metastatic breast cancer is expected to boost the global market growth during the forecast period. For instance, according to the American Society of Clinical Oncology (ASCO), in the United States, around 6% of females have metastatic breast cancer when they are first analyzed.

Breast cancer is the second most typical reason for death from cancer in females in the United States. Also, it is assessed that about 43,700 individuals (43,170 females and 530 males) casualties from this disease will transpire in the United States in 2023. Moreover, according to the American Medical Association, around 20 to 30 percent of early-stage breast cancer evolves as metastatic or stage IV, the most fierce and devastating state of breast cancer, usually ignored until it evolves as challenging to handle.

Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Absence of Efficacious Therapies

However, the absence of efficacious therapies and treatment-related adverse outcomes could restrict the growth of the metastatic breast cancer market during the forecast period. Furthermore, the lack of awareness and professionals are among the additional factors hampering the global market growth.

Segment Analysis

The global metastatic breast cancer market is segmented based on treatment type, route of administration, end user and region.

Immunotherapy Treatment Type is Expected to Dominate Market

Owing to the increasing positive outcomes from clinical investigations and product approvals is expected to boost the segment growth during the forecast period, dominating the global market. For instance, in August 2023, the final analysis of the phase III TROPiCS-02 study published by the Lancet revealed that the antibody-drug conjugate sacituzumab govitecan-hziy persisted to present exceptional advantage for individuals with hormone receptor-positive, HER2-negative metastatic breast cancer when corresponded with classic chemotherapy.

Moreover, in February 2023, Gilead Sciences, Inc. obtained the U.S. Food and Drug Administration (FDA) authorization for its Trodelvy (sacituzumab govitecan-hziy) to treat adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1 + or IHC 2 + /ISH-) breast cancer who have obtained endocrine-based treatment and at short two other systemic treatments in the metastatic setting.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the presence of key market players in North America holding major shares of the global market through distinct market strategies including mergers, acquisitions, expansions, and securing funding, the region is expected to dominate the global market during the forecast period.

For instance, in March 2023, Pfizer Inc and Seagen formed a final coalition contract following which Pfizer Inc intends to acquire Seagen, a global biotechnology corporation involved in the discovery, development, and commercialization of innovative cancer therapies, for $229 in cash per Seagen share for a whole enterprise worth of $43 billion.

Moreover, in October 2022, PIC Therapeutics, Inc., a Massachusetts headquartered biopharmaceutical corporation committed to designing life-changing therapies for individuals with cancer, secured a $35 million Series A financing conducted by OrbiMed.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, there was a significant decrease in cancer diagnosis among breast, colon, and rectal cancers in the first few months, according to a study published in JAMA Network Open. Another study published in the European Journal of Epidemiology reported an overall decrease of approximately 37.3% in diagnostic tests during the pandemic, resulting in 27% fewer cancer diagnoses. This decrease in cancer diagnosis has lowered the demand for cancer therapies.

Market Segmentation

By Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Radiation Therapy

By Route of Administration

  • Oral
  • Parenteral

By End User

  • Hospitals
  • Specialty Clinics
  • Cancer Research Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, Verzenio (abemaciclib) received an expanded indication from the FDA for the adjuvant treatment of adult patients with hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence when used in combination with endocrine therapy (ET).
  • In July 2023, according to initial data from a phase 2 trial being conducted in Europe, Ixabepilone (Ixempra) provided clinical benefit to patients with metastatic breast cancer who had been selected for treatment with the DRP-IXEMPRA companion diagnostic (CDx) candidate.
  • In August 2023, the FDA and Eagle Pharmaceuticals reached a consensus in a Type C meeting to determine the next steps for the development of EA-114, a novel formulation of fulvestrant (Faslodex) and an estrogen receptor antagonist used in the treatment of postmenopausal women with breast cancer.

Competitive Landscape

The major global players in the market include: Hoffmann-La Roche, Pfizer Inc, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Novartis AG among others.

Why Purchase the Report?

  • To visualize the global metastatic breast cancer market segmentation based on treatment type, route of administration, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of metastatic breast cancer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global metastatic breast cancer market report would provide approximately 61 tables, 58 figures and 184 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Absence of Efficacious Therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. Patent Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Chemotherapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immunotherapy
  • 7.4. Hormone Therapy
  • 7.5. Radiation Therapy

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Cancer Research Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Hoffmann-La Roche*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer Inc
  • 12.3. Bristol-Myers Squibb, Inc.
  • 12.4. Boehringer Ingelheim GmbH
  • 12.5. Eli Lilly and Company
  • 12.6. GlaxoSmithKline Plc
  • 12.7. AstraZeneca, Inc.
  • 12.8. Amgen Inc.
  • 12.9. Novartis AG
  • 12.10. Merck and Co. Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us